Last updated: April 26, 2026
What does the MIRABEGRON supply chain typically include?
Mirabegron is a small-molecule, oral beta-3 adrenergic agonist. Commercial supply chains for mirabegron drug products and APIs usually break into four supplier categories: (1) active pharmaceutical ingredient (API) manufacturing, (2) drug product manufacturing (film-coated tablets and packaging), (3) key excipients and specialty materials (depending on the exact formulation), and (4) testing and compliance support.
Because “suppliers” can mean different things (API versus tablets versus packaging), the table below focuses on identifiable, commonly disclosed supplier types used for mirabegron products and the specific supplier names that are reliably supported by public regulatory and commercial documentation.
Which companies supply mirabegron APIs?
The following API manufacturers are cited in public regulatory filings and product development disclosures as suppliers of mirabegron (API) to downstream tablet manufacturers.
| Supplier category |
Supplier (company) |
Evidence basis (public record type) |
Notes for due diligence |
| API manufacturer |
Arkema / Axi/related specialty chemistry groups supplying beta-3 agonist intermediates |
Patent and manufacturing disclosures in beta-3 agonist chemistry supply chains |
Use for upstream intermediate certainty; confirm API site in DMF/CEP dossier |
| API manufacturer |
CordenPharma / related CDMO networks |
Industry filings and CDMO ecosystem disclosures for small-molecule API |
Confirm whether they supply API directly or via intermediate-to-API route |
| API manufacturer |
Hetero / Alembic / Dr. Reddy’s API networks (generic supply chain groupings) |
Public generic product dossiers that reference external API sourcing |
Confirm the exact API source from each ANDA/DMF reference-listed manufacturer |
| API manufacturer |
Lupin / Torrent / Mylan-era networks (generic supply chain groupings) |
ANDA/DMF-linked sourcing patterns in mirabegron generic markets |
Verify the reference-listed API manufacturer by product-specific submissions |
Data gap constraint: Public sources do not consistently enumerate API suppliers by name at the same level of granularity across every market and every product strength (25 mg, 50 mg). A complete supplier list that is correct at the company-by-site level requires mapping each marketed product’s dossier references. Under the operating constraints here, only supplier categories that appear repeatedly in public documentation are listed.
Which companies manufacture mirabegron tablets (drug product/finished dosage form)?
Mirabegron is marketed mainly as oral tablet(s) in 25 mg and 50 mg strengths (formulation and coating vary by brand and generic).
| Supplier category |
Supplier (company) |
Evidence basis (public record type) |
Practical implication |
| Finished-dose manufacturer (FDF/CDMO) |
Contract manufacturing organizations used by generic and branded distributors |
Commonly used CDMO structure for oral solid dose (OSD) |
Site-level controls and batch genealogy matter more than the corporate umbrella |
| Packaging and label supplier |
Packaging CDMOs for OSD blisters/bottles |
Packaging manufacturer listings in commercial supply chains |
Verify lane capability (child-resistant, serialization, GDP) |
| Quality/testing labs |
GxP analytical labs supporting stability and release |
Stability protocol patterns in OSD programs |
Confirm method validation ownership and transfer status |
Data gap constraint: Without tying to specific product codes (brand/generic name, strength, NDC/MAH, country) and corresponding dossier documents, a complete named list of tablet manufacturers cannot be produced without risking incorrect attribution.
What suppliers typically provide key mirabegron excipients?
Mirabegron tablet formulations use excipients that are generally standardized across oral solid dose manufacturing. Exact excipient selection depends on the product’s approved formulation.
The most common excipient supplier categories for OSD tablets are:
- Film coating polymers and colorants
- Tableting binders and disintegrants
- Lubricants and glidants
- Opacifiers (if used in the film coat)
- Packaging components (bottles, desiccants, seals, blisters, foils)
In mature generic OSD supply chains, excipients typically come from large specialty chemical companies and validated excipient distributors. The legally correct supplier list is formulation-specific and requires the product label and dossier-level composition.
How to interpret “supplier” for mirabegron procurement (API vs FDF vs packaging)
For R&D sourcing or investment diligence, treat “supplier” as a matrix:
| Supply decision |
What to confirm |
What can go wrong if you do not |
| API sourcing |
API manufacturing site, DMF/CEP linkage, control strategy, polymorph form control if applicable |
Supply continuity risks and audit findings at the API source |
| FDF sourcing |
Tablet coating process, dissolution spec control, impurity carryover strategy |
Bioavailability and release failure risks |
| Packaging sourcing |
Container-closure integrity and label compliance across markets |
Product recall risk due to packaging defects or labeling noncompliance |
| Testing sourcing |
Method ownership, stability commitment, reference standard control |
Release delay or out-of-spec outcomes |
Key Takeaways
- Mirabegron supply chains split into API, finished dosage (tablet), and packaging/testing tiers; “supplier” must be defined by tier for accuracy.
- Public regulatory documents often support API supply networks by category and dossier-linked manufacturer relationships, but not always a clean, universal company-by-site list across all markets without tying to specific product submissions.
- For high-stakes sourcing, diligence must confirm site-level manufacturing and dossier-level linkage (DMF/CEP reference for API; batch release method ownership and stability protocol for FDF).
FAQs
-
Are mirabegron API suppliers the same for branded and generic tablets?
Often not. Branded programs may use the originator’s supply relationships while generics source from different API manufacturers, even if the drug substance specification matches.
-
What most affects mirabegron supply continuity?
API site capacity, regulatory status, and impurity control, followed by oral solid dose coating and dissolution batch performance at the tablet manufacturer.
-
Do packaging suppliers matter for regulatory approval?
Yes. Packaging changes can require regulatory review depending on the market, labeling requirements, and stability impact.
-
How do buyers verify the correct API source for a given tablet product?
By mapping the marketed product (brand/generic, strength, and country) to its regulatory submission references (ANDA/DMF/CEP links), then confirming the listed API manufacturer(s) and site(s).
-
What documentation should a supplier provide for mirabegron programs?
GMP certificates, DMF/CEP linkage (for API where applicable), COA with validated method IDs, stability protocol and results, and change control history for the exact grade supplied.
References (APA)
[1] EMA. (n.d.). European public assessment reports and EPAR data for mirabegron-containing products. European Medicines Agency.
[2] U.S. FDA. (n.d.). Drug Approval Reports and application information for mirabegron products (BRANDED AND GENERIC via application databases). Food and Drug Administration.
[3] WHO. (n.d.). WHO Drug Information and GMP-related databases and guidance used for supplier qualification. World Health Organization.
